Research progress on inhibitors and degraders of the main protease of SARS-CoV-2
10.12206/j.issn.2097-2024.202503064
- VernacularTitle:SARS-CoV-2主蛋白酶抑制剂和降解剂研究进展
- Author:
Lai WEI
1
;
Guoqiang DONG
1
Author Information
1. Department of Medicinal Chemistry, School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Publication Type:Reviews
- Keywords:
severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）;
main protease;
inhibitors;
degraders;
antiviral agents
- From:
Journal of Pharmaceutical Practice and Service
2025;43(6):259-269
- CountryChina
- Language:Chinese
-
Abstract:
The main protease （Mpro） of SARS-CoV-2, a pivotal enzyme for viral replication and transcription, has emerged as a critical therapeutic target in antiviral drug discovery due to its high conservation across coronaviruses and low homology with host proteases. Recent advances in Mpro inhibitors were summarized in this review, including peptide-mimetic covalent inhibitors, non-peptide covalent inhibitors, and non-covalent inhibitors. Furthermore, the application of proteolysis targeting chimera （PROTAC） technology in developing Mpro degraders was explored, which provided valuable insights for the development of antiviral drugs.
